CDKN1C/p57kip2 is a Candidate Tumor Suppressor Gene in Human Breast Cancer

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2008 Mar 8

PMID 18325103

Citations 34

Authors

Pamela S Larson

Benjamin L Schlechter

Chia-Lin King

Qiong Yang

Chelsea N Glass

Charline Mack

Robert Pistey

Antonio de las Morenas

Carol L Rosenberg

Affiliations

Soon will be listed here.

Abstract

Background: CDKN1C (also known as p57KIP2) is a cyclin-dependent kinase inhibitor previously implicated in several types of human cancer. Its family members (CDKN1A/p21CIP1 and B/p27KIP1) have been implicated in breast cancer, but information about CDKN1C's role is limited. We hypothesized that decreased CDKN1C may be involved in human breast carcinogenesis in vivo.

Methods: We determined rates of allele imbalance or loss of heterozygosity (AI/LOH) in CDKN1C, using an intronic polymorphism, and in the surrounding 11p15.5 region in 82 breast cancers. We examined the CDKN1C mRNA level in 10 cancers using quantitative real-time PCR (qPCR), and the CDKN1C protein level in 20 cancers using immunohistochemistry (IHC). All samples were obtained using laser microdissection. Data were analyzed using standard statistical tests.

Results: AI/LOH at 11p15.5 occurred in 28/73 (38%) informative cancers, but CDKN1C itself underwent AI/LOH in only 3/16 (19%) cancers (p = ns). In contrast, CDKN1C mRNA levels were reduced in 9/10 (90%) cancers (p < 0.0001), ranging from 2-60% of paired normal epithelium. Similarly, CDKN1C protein staining was seen in 19/20 (95%) cases' normal epithelium but in only 7/14 (50%) cases' CIS (p < 0.004) and 5/18 (28%) cases' IC (p < 0.00003). The reduction appears primarily due to loss of CDKN1C expression from myoepithelial layer cells, which stained intensely in 17/20 (85%) normal lobules, but in 0/14 (0%) CIS (p < 0.00001). In contrast, luminal cells displayed less intense, focal staining fairly consistently across histologies. Decreased CDKN1C was not clearly associated with tumor grade, histology, ER, PR or HER2 status.

Conclusion: CDKN1C is expressed in normal epithelium of most breast cancer cases, mainly in the myothepithelial layer. This expression decreases, at both the mRNA and protein level, in the large majority of breast cancers, and does not appear to be mediated by AI/LOH at the gene. Thus, CDKN1C may be a breast cancer tumor suppressor.

Citing Articles

dCas9-HDAC8-EGFP fusion enables epigenetic editing of breast cancer cells by H3K9 deacetylation.

Rahman M, Tollefsbol T Eur J Cell Biol. 2024; 103(4):151463.

PMID: 39437453 PMC: 11677611. DOI: 10.1016/j.ejcb.2024.151463.

SRY-box transcription factor 21 antisense divergent transcript 1: Regulatory roles and clinical significance in neoplastic conditions and Alzheimer's Disease.

Lei L, Peng G, Luo H, Li W J Cancer. 2023; 14(17):3258-3274.

PMID: 37928430 PMC: 10622988. DOI: 10.7150/jca.89619.

Characterization of tumor microenvironment infiltration and therapeutic responses of cell cycle-related genes' signature in breast cancer.

Wu H, Chen Y, Li M, Chen Z, Liu J, Lai G J Cancer Res Clin Oncol. 2023; 149(15):13889-13904.

PMID: 37540256 DOI: 10.1007/s00432-023-05198-9.

Preconditioned Chorionic Villus Mesenchymal Stem/Stromal Cells (CVMSCs) Minimize the Invasive Phenotypes of Breast Cancer Cell Line MDA231 In Vitro.

Subayyil A, Basmaeil Y, Kulayb H, Alrodayyan M, Alhaber L, N Almanaa T Int J Mol Sci. 2023; 24(11).

PMID: 37298519 PMC: 10253955. DOI: 10.3390/ijms24119569.

CDKN1C as a prognostic biomarker correlated with immune infiltrates and therapeutic responses in breast cancer patients.

Lai J, Lin X, Cao F, Mok H, Chen B, Liao N J Cell Mol Med. 2021; 25(19):9390-9401.

PMID: 34464504 PMC: 8500970. DOI: 10.1111/jcmm.16880.

References

Fan G, Xu F, Yang B, Fujieda S . p57(kip2) expression is related to carcinogenesis and tumor progression in laryngeal tissues. Acta Otolaryngol. 2006; 126(3):301-5. DOI: 10.1080/00016480500388851. View

Pateras I, Apostolopoulou K, Koutsami M, Evangelou K, Tsantoulis P, Liloglou T . Downregulation of the KIP family members p27(KIP1) and p57(KIP2) by SKP2 and the role of methylation in p57(KIP2) inactivation in nonsmall cell lung cancer. Int J Cancer. 2006; 119(11):2546-56. DOI: 10.1002/ijc.22214. View

Toyoshima H, Hunter T . p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell. 1994; 78(1):67-74. DOI: 10.1016/0092-8674(94)90573-8. View

Matsuoka S, Thompson J, Edwards M, Bartletta J, Grundy P, Kalikin L . Imprinting of the gene encoding a human cyclin-dependent kinase inhibitor, p57KIP2, on chromosome 11p15. Proc Natl Acad Sci U S A. 1996; 93(7):3026-30. PMC: 39755. DOI: 10.1073/pnas.93.7.3026. View

Tokino T, Urano T, Furuhata T, Matsushima M, Miyatsu T, Sasaki S . Characterization of the human p57KIP2 gene: alternative splicing, insertion/deletion polymorphisms in VNTR sequences in the coding region, and mutational analysis. Hum Genet. 1996; 97(5):625-31. DOI: 10.1007/BF02281873. View

Lakhani S, Bissell M . Introduction: the role of myoepithelial cells in integration of form and function in the mammary gland. J Mammary Gland Biol Neoplasia. 2006; 10(3):197-8. DOI: 10.1007/s10911-005-9580-x. View

Rosenberg C, Finnemore E, Larson P, Nogueira C, Delaney T . DNA alterations in tumor scrapes vs. biopsies of squamous-cell carcinomas of the head and neck. Int J Cancer. 2001; 89(2):105-10. DOI: 10.1002/(sici)1097-0215(20000320)89:2<105::aid-ijc1>3.0.co;2-o. View

Schlechter B, Yang Q, Larson P, Golubeva A, Blanchard R, de las Morenas A . Quantitative DNA fingerprinting may distinguish new primary breast cancer from disease recurrence. J Clin Oncol. 2004; 22(10):1830-8. DOI: 10.1200/JCO.2004.05.123. View

Kerangueven F, Noguchi T, Coulier F, Allione F, Wargniez V, Simony-Lafontaine J . Genome-wide search for loss of heterozygosity shows extensive genetic diversity of human breast carcinomas. Cancer Res. 1998; 57(24):5469-74. View

10.

Matsuoka S, Edwards M, Bai C, Parker S, Zhang P, Baldini A . p57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene. Genes Dev. 1995; 9(6):650-62. DOI: 10.1101/gad.9.6.650. View

11.

Thompson J, Reese K, DeBaun M, Perlman E, Feinberg A . Reduced expression of the cyclin-dependent kinase inhibitor gene p57KIP2 in Wilms' tumor. Cancer Res. 1996; 56(24):5723-7. View

12.

Liu J, Kahri A, Heikkila P, Voutilainen R . Ribonucleic acid expression of the clustered imprinted genes, p57KIP2, insulin-like growth factor II, and H19, in adrenal tumors and cultured adrenal cells. J Clin Endocrinol Metab. 1997; 82(6):1766-71. DOI: 10.1210/jcem.82.6.3968. View

13.

Oya M, Schulz W . Decreased expression of p57(KIP2)mRNA in human bladder cancer. Br J Cancer. 2000; 83(5):626-31. PMC: 2363522. DOI: 10.1054/bjoc.2000.1298. View

14.

Moggs J, Murphy T, Lim F, Moore D, Stuckey R, Antrobus K . Anti-proliferative effect of estrogen in breast cancer cells that re-express ERalpha is mediated by aberrant regulation of cell cycle genes. J Mol Endocrinol. 2005; 34(2):535-51. DOI: 10.1677/jme.1.01677. View

15.

Hsu S, Lewis J, Borke J, Singh B, Dickinson D, Caughman G . Chemopreventive effects of green tea polyphenols correlate with reversible induction of p57 expression. Anticancer Res. 2002; 21(6A):3743-8. View

16.

Lee M, Reynisdottir I, Massague J . Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev. 1995; 9(6):639-49. DOI: 10.1101/gad.9.6.639. View

17.

Ito Y, Takeda T, Wakasa K, Tsujimoto M, Matsuura N . Expression of p57/Kip2 protein in pancreatic adenocarcinoma. Pancreas. 2001; 23(3):246-50. DOI: 10.1097/00006676-200110000-00004. View

18.

Jones C, Mackay A, Grigoriadis A, Cossu A, Reis-Filho J, Fulford L . Expression profiling of purified normal human luminal and myoepithelial breast cells: identification of novel prognostic markers for breast cancer. Cancer Res. 2004; 64(9):3037-45. DOI: 10.1158/0008-5472.can-03-2028. View

19.

Ito Y, Takeda T, Sakon M, Tsujimoto M, Monden M, Matsuura N . Expression of p57/Kip2 protein in hepatocellular carcinoma. Oncology. 2001; 61(3):221-5. DOI: 10.1159/000055378. View

20.

Larson P, Ungarelli R, de las Morenas A, Cupples L, Rowlings K, Palmer J . In utero exposure to diethylstilbestrol (DES) does not increase genomic instability in normal or neoplastic breast epithelium. Cancer. 2006; 107(9):2122-6. DOI: 10.1002/cncr.22223. View